SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that…
Biotechnology
US, Stamford [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 6.83 | 6.85 | 6.41 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -30.70 | 1.20 | 1.73 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -9.73 | 7.69 | 8.52 | |
| Cash | -9.24 | 5.92 | 6.52 | |
| Capex | -75.03 | < 0.005 | 0.03 | |
| Free Cash Flow | -31.12 | -1.08 | -0.82 | |
| Revenue | 284.17 | 0.28 | 0.07 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 10.24 | 0.91 | 0.82 | |
| Operating Margin | 75.26 | -4.47 | -18.08 | |
| ROA | -2.37 | -0.13 | -0.13 | |
| ROE | -2.24 | -0.15 | -0.15 | |
| ROIC | -11.90 | -0.16 | -0.15 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of SWTX is permitted for members.
5
Growth
The "Growth Entry" for the Focus of SWTX is permitted for members.
6
Leverage & Liquidity